What is a solitary fibrous tumour?
A solitary fibrous tumour (SFT) is a rare tumour of the body’s connective (fibroblastic) tissue. It was first described in the lining of the lungs (the pleura), but it can grow almost anywhere, including the abdomen, pelvis, head and neck, limbs and the coverings of the brain (meninges).
Every SFT carries the same gene change, a fusion of two genes called NAB2 and STAT6. In the past, many of these tumours were called haemangiopericytoma. The World Health Organization (WHO) now groups them all as solitary fibrous tumours.
Most SFTs grow slowly and are cured by complete surgical removal. However, SFT is classed as a sarcoma of intermediate or malignant behaviour. A minority come back or spread, sometimes 10-20 years later, so long-term follow-up is advised.
1. How common is it?
| Feature | Details |
|---|---|
| Frequency | Rare; classed as an ultra-rare sarcoma. SFT of the brain and spinal cord coverings affects about 0.38 people per million per year in US data |
| Age | Mostly adults aged 40-70; uncommon in children |
| Sex | Men and women are affected about equally |
| Sites | The chest (pleura) and the abdomen and pelvis are the most common sites; also the head and neck (including the nose, sinuses and eye socket), limbs, trunk and meninges |
| Behaviour | Distant spread (metastasis) occurs in about 5-25% of cases |
2. Causes and types
2.1 The NAB2-STAT6 fusion
The cause of SFT is a gene change inside the tumour cells. Two neighbouring genes on chromosome 12 (12q13), NAB2 and STAT6, become joined. In 2013, this NAB2-STAT6 fusion was found in all 51 SFTs tested in one landmark study.
The fusion turns NAB2, which normally acts as a brake on growth signals, into an activator that switches growth genes on. The change is acquired, not inherited. No lifestyle cause, such as smoking or asbestos, has been shown to cause SFT.
2.2 Types of SFT
| Type | Features | Usual behaviour |
|---|---|---|
| Typical (classic) SFT | Few cell divisions and no dead tissue | Usually cured by surgery, although late recurrence is possible |
| Malignant SFT | More cell divisions (historically 4 or more per 10 high-power fields), often with dead tissue (necrosis) or crowded, atypical cells | Higher risk of recurrence and spread |
| Dedifferentiated SFT | Part of the tumour turns into a high-grade sarcoma that no longer looks like SFT | Aggressive; behaves like a high-grade sarcoma |
| SFT of the central nervous system | Arises from the meninges; graded 1 to 3 in the 2021 WHO classification of brain tumours | Can recur locally and spread outside the brain |
Today, doctors rely less on the “benign versus malignant” label and more on risk scores that estimate the chance of spread (see section 6).
3. How does it look?
3.1 The tumour itself
| Feature | Typical appearance |
|---|---|
| Shape | A well-defined, rounded or lobulated mass, often with a thin capsule. In the chest it may hang from the pleura on a stalk |
| Size | From 1-2 cm to more than 20 cm; tumours in the chest, abdomen and pelvis are often large when found |
| Cut surface | Firm, white to grey-tan, with a whorled look; larger or malignant tumours may contain cysts, bleeding or necrosis |
| Blood supply | Very rich, with many large vessels feeding the tumour |
3.2 On scans
| Test | Typical findings |
|---|---|
| CT | A large, sharply outlined soft-tissue mass that enhances strongly with contrast, often with prominent vessels; it pushes nearby organs aside rather than invading them |
| MRI | Mixed signal on T2-weighted images and strong enhancement; flow voids from large vessels, which is especially useful for meningeal and head and neck tumours |
| PET-CT | Usually low to moderate uptake; higher uptake may suggest malignant or dedifferentiated tumours |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Spindle-shaped to oval cells arranged without a clear pattern (“patternless” growth) |
| Background | Alternating cell-rich and cell-poor areas with bands of thick collagen |
| Vessels | Branching, thin-walled vessels shaped like a deer’s antlers (staghorn or haemangiopericytoma-like vessels) |
| Signs of higher risk | Numerous cell divisions, necrosis, high cellularity and atypical nuclei |
3.4 Special stains and tests
| Test | Typical result | Why it matters |
|---|---|---|
| STAT6 (nuclear staining) | Positive in about 98% of SFTs | The key diagnostic test. It is highly specific; only a few other tumours, such as some dedifferentiated liposarcomas, show weak staining |
| CD34 | Positive in most | Helpful but not specific |
| GRIA2 | Positive in about 80% | Can support the diagnosis when STAT6 is unclear |
| Molecular testing (RNA sequencing) | Shows the NAB2-STAT6 fusion | Confirms difficult cases; standard FISH often fails because the two genes lie so close together |
| Other markers (keratins, S100, desmin, MDM2) | Usually negative | Help exclude mimics such as synovial sarcoma, mesothelioma, nerve sheath tumours and liposarcoma |
4. Symptoms
Many SFTs cause no symptoms and are found by chance on a scan. Others are found because of a slowly growing lump or because the tumour presses on nearby structures.
4.1 Symptoms by site
| Site | Typical symptoms |
|---|---|
| Chest (pleura or lung) | Cough, shortness of breath or chest discomfort, especially with large tumours; many people have no symptoms |
| Abdomen, pelvis or retroperitoneum | A swelling or feeling of fullness, abdominal pain, early fullness after eating, or bladder and bowel problems from pressure |
| Limbs and trunk | A painless, slowly growing, deep lump |
| Nose, sinuses or eye socket | Blocked nose, nosebleeds, a bulging eye or double vision |
| Meninges (brain or spine) | Headache, seizures, weakness or other nerve symptoms depending on the location |
4.2 Paraneoplastic syndromes
Large SFTs can release substances that affect the whole body.
| Syndrome | What happens |
|---|---|
| Doege-Potter syndrome | The tumour makes an incompletely processed form of IGF-2 (a hormone that acts like insulin), causing low blood sugar (hypoglycaemia). Symptoms include sweating, shakiness, confusion and even loss of consciousness. It affects about 5% of patients, more often those with large or malignant tumours, and usually resolves after complete removal |
| Pierre Marie-Bamberger syndrome | Clubbing of the fingers and painful joints (hypertrophic osteoarthropathy), mainly with large chest tumours |
When to see a doctor: a lump that keeps growing, unexplained episodes of low blood sugar, or persistent cough, breathlessness or abdominal swelling should be investigated.
5. Diagnosis
5.1 Imaging
CT or MRI shows the size and position of the tumour and its relationship to nearby organs and blood vessels. A CT of the chest checks for lung metastases. Scans of the whole body may be added for malignant tumours.
5.2 Biopsy
A core needle biopsy under image guidance usually confirms the diagnosis before surgery. Small, easily removed tumours may instead be removed completely and then examined. The ESMO sarcoma guideline recommends that biopsy and treatment take place in, or in collaboration with, a specialist sarcoma centre.
5.3 Blood tests
Blood sugar is checked, especially if there are symptoms of hypoglycaemia. In Doege-Potter syndrome, insulin levels are low, and the ratio of IGF-2 to IGF-1 is raised (usually above 10).
6. Risk assessment
SFT does not have a specific staging system. Instead, doctors estimate the risk of spread with a risk model. The most widely used is the model developed at MD Anderson Cancer Center (Demicco and colleagues, refined in 2017).
| Factor | Points |
|---|---|
| Age | Under 55 = 0; 55 or older = 1 |
| Tumour size | Under 5 cm = 0; 5 to under 10 cm = 1; 10 to under 15 cm = 2; 15 cm or more = 3 |
| Cell divisions (mitoses per 10 high-power fields) | 0 = 0; 1-3 = 1; 4 or more = 2 |
| Tumour necrosis | Under 10% = 0; 10% or more = 1 |
| Risk group | Total points | Risk of metastasis in the 2017 study |
|---|---|---|
| Low | 0-3 | No metastases at 10 years (66% of patients) |
| Intermediate | 4-5 | About 10% at 10 years (24% of patients) |
| High | 6-7 | About 73% at 5 years (10% of patients) |
The French Sarcoma Group has also developed a risk calculator that includes tumour site and mitotic count. Meningeal SFTs use their own WHO grading.
7. Treatment
Treatment is planned by a sarcoma multidisciplinary team.
7.1 Surgery
Complete surgical removal with clear margins is the main and potentially curative treatment.
- For pleural SFT, the tumour is often attached by a stalk and can be removed with a small rim of lung or chest wall, sometimes by keyhole surgery.
- Abdominal, pelvic and retroperitoneal tumours can be large and very vascular. Some patients have the feeding vessels blocked (embolisation) before surgery to reduce bleeding.
- For meningeal SFT, the aim is complete removal whenever it is safe.
7.2 Radiotherapy
| Situation | Role of radiotherapy |
|---|---|
| After incomplete removal or with close margins | Can improve local control, especially for tumours in the head and neck, pelvis or meninges |
| Meningeal SFT | In US SEER data, gross total resection plus radiotherapy was linked to better survival than resection alone |
| Inoperable or recurrent tumours | Can control growth and relieve symptoms |
Side effects depend on the area treated and include tiredness, skin changes and, depending on the site, bowel, bladder or nerve effects.
7.3 Drug treatment for advanced disease
Standard sarcoma chemotherapy has limited activity in most SFTs. Antiangiogenic drugs, which block the tumour’s blood supply, have shown the best results.
| Treatment | Evidence | Main side effects |
|---|---|---|
| Pazopanib (tablet) | In two phase II trials, partial responses (by Choi criteria) were seen in 51% of patients with malignant SFT and 58% with typical SFT | High blood pressure, diarrhoea, tiredness, liver test changes |
| Temozolomide plus bevacizumab | In a retrospective series of 14 patients, 79% had a partial response by Choi criteria; median progression-free survival was 9.7 months | Low blood counts, tiredness, high blood pressure |
| Anthracycline-based chemotherapy (e.g. doxorubicin) | Used mainly for dedifferentiated SFT, which responded poorly to pazopanib | Low blood counts, hair loss, nausea, heart strain |
| Clinical trials | Other targeted drugs and immunotherapy are being studied | Vary by drug |
7.4 Treatment of Doege-Potter syndrome
Complete removal of the tumour usually cures the low blood sugar. Before surgery, or when surgery is not possible, frequent meals, glucose and glucocorticoids can help. Radiotherapy, embolisation and drug treatment may also reduce the tumour’s IGF-2 output.
8. Outlook
Most people with an SFT that is completely removed do well. The main concerns are local recurrence and late metastasis.
| Factor | What the evidence shows |
|---|---|
| Overall | In an MD Anderson series of 103 resected tumours, 5- and 10-year disease-specific survival was 89% and 73% |
| Late relapse | In a French Sarcoma Group study, local recurrence reached 19.2% at 10 years and 38.6% at 20 years. Metastasis reached 31.4% and 49.8%, showing that relapses can be delayed |
| Very late recurrences | In an Italian series, the median time to first recurrence was 12 years (range 10-23), and some “typical” tumours later spread |
| By risk group | Low-risk tumours rarely metastasise; high-risk tumours often do |
| Meningeal SFT | 5- and 10-year survival of 78% and 61% in US SEER data |
| Sites of spread | Most often the lungs, liver and bones |
Factors linked to a worse outlook include older age, large size, high mitotic count, necrosis, dedifferentiation, incomplete removal and a site other than the limbs.
9. Follow-up and living with SFT
9.1 Follow-up
Because recurrences can appear after many years, long-term follow-up is recommended, with intervals based on the risk group.
| Part of follow-up | Details |
|---|---|
| Clinical review | Examination and symptom check |
| Scans of the original site | MRI or CT, more often in the first years |
| Chest CT | To look for lung metastases, especially for intermediate- and high-risk tumours |
| Blood sugar | If Doege-Potter syndrome was present |
9.2 Everyday life
- After complete removal of a low-risk tumour, most people return to normal life.
- Report any new lump, pain, cough or episodes of low blood sugar promptly, even many years later.
- Support is available from sarcoma specialist nurses and sarcoma patient organisations.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is a solitary fibrous tumour cancer? | It is classed as a sarcoma. Many behave like benign tumours, but some recur or spread, so it is treated and followed up in sarcoma centres |
| Is it inherited? | No. The NAB2-STAT6 fusion arises only in the tumour and is not passed on |
| Is it caused by asbestos? | No. Pleural SFT is different from mesothelioma and is not linked to asbestos |
| Why do I need follow-up for so long? | Recurrence and spread can happen more than 10 years after surgery |
| What is the difference between SFT and haemangiopericytoma? | They are now considered the same disease; haemangiopericytoma is an older name |
| Can it be treated if it spreads? | Yes. Surgery, radiotherapy and antiangiogenic drugs such as pazopanib can control the disease, often for long periods |
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Louis, D.N. et al. (2021) ‘The 2021 WHO classification of tumors of the central nervous system: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Robinson, D.R. et al. (2013) ‘Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing’, Nature Genetics, 45(2), pp. 180-185.
- Chmielecki, J. et al. (2013) ‘Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors’, Nature Genetics, 45(2), pp. 131-132.
- Doyle, L.A. et al. (2014) ‘Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics’, Modern Pathology, 27(3), pp. 390-395.
- Vivero, M. et al. (2014) ‘GRIA2 is a novel diagnostic marker for solitary fibrous tumour identified through gene expression profiling’, Histopathology, 65(1), pp. 71-80.
- Demicco, E.G. et al. (2012) ‘Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model’, Modern Pathology, 25(9), pp. 1298-1306.
- Demicco, E.G. et al. (2017) ‘Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model’, Modern Pathology, 30(10), pp. 1433-1442.
- Salas, S. et al. (2017) ‘Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database’, Annals of Oncology, 28(8), pp. 1979-1987.
- Baldi, G.G. et al. (2013) ‘Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients’, Clinical Sarcoma Research, 3, 4.
- Kinslow, C.J. et al. (2018) ‘Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study’, Journal of Neuro-Oncology, 138(1), pp. 173-182.
- Han, G. et al. (2017) ‘Doege-Potter syndrome: a review of the literature including a new case report’, Medicine, 96(27), e7417.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Martin-Broto, J. et al. (2019) ‘Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial’, The Lancet Oncology, 20(1), pp. 134-144.
- Martin-Broto, J. et al. (2020) ‘Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial’, The Lancet Oncology, 21(3), pp. 456-466.
- Park, M.S. et al. (2011) ‘Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor’, Cancer, 117(21), pp. 4939-4947.
- National Cancer Institute (2026) Solitary fibrous tumor (C7634). NCI Thesaurus. Available at: https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C7634 (Accessed: October 2026).
Prepared by the editorial team, October 2026.